Golden Recursion Inc. logoGolden Recursion Inc. logo
Advanced Search
Encellin

Encellin

Encellin is a biotechnology company developing diabetes therapeutics using insulin responsive cells.

Encellin is a biotechnology company based in San Francisco. Encellin is developing diabetes therapeutics using insulin responsive cells. Encellin aims to safely replace missing, damaged, or diseased cells in the body with next generation cell transplants.

In type 1 diabetes (T1D), if the cells that measure sugar and secrete insulin are missing, Encelling performs transplants. However, they are done in only the most severe cases.

Encellin is developing a novel thin-film cell encapsulation device for cell-based therapeutics. With an initial focus on diabetes Encellin plans to encapsulate and replace the cells responsible for making insulin, enabling patients to manage their disease, and have better control over their blood glucose levels.

Timeline

August 9, 2021
Encellin raises $5.9M in Seed financing.
August 9, 2021
Encellin raises a $5,900,000 seed round.

Funding rounds

Patents

Further Resources

Title
Author
Link
Type
Date

Biotech Startups vs Diabetes: Will Encellin Break the Mould?

Darren Wall

Web

Cell Replacement and Type 1 Diabetes: Encellin's Solution

Web

January 2, 2018

Encellin - The Stem Cellar

Web

September 5, 2019

Encellin is Developing a Cell Therapy Technology to Address Type I Diabetes | Medgadget

Web

Grace Wei's Journey from Academia to Encellin Co-Founder and Entrepreneur

Gail Dutton

Web

October 5, 2020

News

Title
Author
Date
Publisher
Description
FinSMEs
August 9, 2021
FinSMEs
About | Advertise | Contact | Disclaimer | News | The Daily Deal Newsletter FinSMEs.com by FinSMEs is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Unported License.

References

Golden logo
By using this site, you agree to our Terms & Conditions.